Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?
- 31 January 1998
- journal article
- review article
- Published by Elsevier in Immunology Today
- Vol. 19 (1), 2-5
- https://doi.org/10.1016/s0167-5699(97)01191-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- TAP off - tumors onImmunology Today, 1997
- Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44V6-specific SCFV: ζ-chimeraInternational Journal of Cancer, 1996
- Alterations in T cells of cancer-bearers: whence specificity?Immunology Today, 1996
- Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevanceImmunology Today, 1995
- Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes.The Journal of Experimental Medicine, 1995
- Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.The Journal of Experimental Medicine, 1993
- Sequence requirements for induction of cytolysis by the T cell antigenFc receptor ζ chainCell, 1992
- Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptidesCell, 1991
- The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysCell, 1991
- Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and StrategiesJNCI Journal of the National Cancer Institute, 1989